Hepaglide vs Ozempic: Comparison Guide

Hepaglide vs Ozempic: Comparison Guide

If you are comparing Hepaglide and Ozempic, the key point is that both are being discussed as semaglutide brands. Hepaglide is not pemvidutide and should not be framed as a dual GLP-1/glucagon research drug.

This guide compares the products using the correct India-market context so you can discuss them more clearly with your doctor. Consult your healthcare provider before starting any medication.

What is Ozempic?

Ozempic is Novo Nordisk's brand for semaglutide, a GLP-1 receptor agonist. It is commonly used in adults with type 2 diabetes and is also widely discussed because semaglutide can reduce appetite and support weight change in some patients.

Ozempic is given as a once-weekly injection. Novo Nordisk launched it in India in December 2025, where it is approved and marketed for adults with type 2 diabetes.

What is Hepaglide?

Hepaglide is an Alkem semaglutide injection brand in India. Alkem's launch materials list Semasize, Obesema, and Hepaglide as its semaglutide brands and describe DCGI approval for manufacturing and marketing in India for type 2 diabetes and chronic weight management (as an adjunct to diet and exercise).

That means Hepaglide belongs in a semaglutide brand comparison, not in an investigational pemvidutide discussion.

What they have in common

Hepaglide and Ozempic share the same active ingredient: semaglutide.

That means both are discussed in relation to:

• improved glucose control in type 2 diabetes
• slower gastric emptying
• reduced appetite in many users
• weekly injection-based treatment plans

Key differences: Hepaglide vs Ozempic

1. Manufacturer

• Ozempic is made by Novo Nordisk.
• Hepaglide is associated with Alkem in India.

2. India-market positioning

Ozempic is the originator semaglutide brand with global recognition. Hepaglide is part of the newer India-market rollout of semaglutide from a domestic manufacturer.

3. Device and access context

Alkem described both disposable and reusable pen options across its semaglutide launch. Ozempic has its own established pen system. Device workflow and refill experience may therefore differ.

4. Evidence base

Most landmark semaglutide trial data are tied to the broader originator evidence base. Clinicians still use that semaglutide evidence when discussing Hepaglide while also checking local product details and approval context.

Side effects and safety

Because both are semaglutide-based, the expected side-effect pattern is broadly similar. Common effects may include:

• nausea
• vomiting
• diarrhoea
• constipation
• abdominal discomfort
• lower appetite

These effects are often more noticeable when starting treatment or after dose increases.

Serious but less common risks are also shared: pancreatitis (seek urgent help for severe, persistent abdominal pain that may spread to the back), gallbladder problems, dehydration and kidney problems with severe vomiting or diarrhoea, low blood sugar if combined with insulin or a sulfonylurea, worsening diabetic eye disease, and aspiration risk under anaesthesia or sedation. Semaglutide should not be used in pregnancy. See our Hepaglide side effects guide for details.

Bottom line

Hepaglide and Ozempic are both semaglutide injection brands. The main differences are brand, manufacturer, device, and local market context—Alkem's Hepaglide in India versus Novo Nordisk's Ozempic—not a semaglutide-versus-pemvidutide comparison.

A clinician can help you compare those practical differences safely. Consult your healthcare provider before starting any medication.

Sources

• https://admin.alkemlabs.com/uploads/Press_Release_Alkem_Semaglutide_Day_1_launch_final_fc1e90e3be.pdf
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf
• https://cdsco.gov.in/opencms/opencms/en/Home/
• https://www.theweek.in/news/health/2025/12/12/ozempic-arrives-in-india-novo-nordisk-s-weekly-flex-touch-pen-injection-price-set-at-rs-2-200.amp.html
• https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
• https://medlineplus.gov/druginfo/meds/a618008.html